Oragenics, Inc. (NYSE MKT: OGEN) (the
“Company”) announced today that it has completed its previously
announced underwritten public offering of 4,400,000 shares of common
stock at a public offering price of $2.50 per share. The net proceeds to
the company, after underwriting discounts and commissions and estimated
offering expenses, were $9,847,500.
Griffin Securities was the sole underwriter for the offering.
The Company filed a registration statement on Form S-3, as well as a
final prospectus supplement and accompanying prospectus, with the
Securities and Exchange Commission. The final prospectus supplement and
accompanying prospectus relating to the offering may be obtained by
sending a request to Griffin Securities, Inc., by calling (212) 509-9500
or by mail at Griffin Securities, Inc. 17 State Street New York, NY
10004.
This press release does not constitute an offer to sell or a
solicitation of an offer to buy the securities in this offering.
About Oragenics, Inc.
Oragenics, Inc. is focused on becoming the world leader in novel
antibiotics against infectious disease and probiotics for oral health
for humans and pets. Oragenics has established exclusive worldwide
channel collaborations for lantibiotics and probiotics, with Intrexon
Corporation Inc., a leading synthetic biology company. The lantibiotics
collaboration allows Oragenics access to Intrexon’s proprietary
technologies to accelerate the development of much needed new
antibiotics that will work against resistant strains of bacteria. The
probiotics collaboration allows Oragenics access to Intrexon’s
proprietary technologies to develop and commercialize probiotics,
specifically the direct administration to humans of genetically
engineered probiotics for the treatment of diseases of the oral cavity,
throat, sinus and esophagus, including, but not limited to, aphthous
stomatitis and Behcet’s disease. Oragenics also develops, markets and
sells proprietary probiotics specifically designed to enhance oral
health for humans and pets, under the brand names Evora and ProBiora in
over 13 countries worldwide.
Safe Harbor Statement: Under the Private Securities Litigation
Reform Act of 1995: This release includes forward-looking statements
that reflect the Company’s current views with respect to future events
and financial performance. These forward-looking statements are based on
management’s beliefs and assumptions and information currently
available. The words “believe,” “expect,” “anticipate,” “intend,”
“estimate,” “project” and similar expressions that do not relate solely
to historical matters identify forward-looking statements. Investors
should be cautious in relying on forward-looking statements because they
are subject to a variety of risks, uncertainties, and other factors that
could cause actual results to differ materially from those expressed in
any such forward-looking statements. These factors include, but are not
limited to our ability to raise additional capital to sustain our
operations and those set forth in our most recently filed annual report
on Form 10-K and quarterly report on Form 10-Q, and other factors
detailed from time to time in filings with the U.S. Securities and
Exchange Commission. We expressly disclaim any responsibility to update
forward-looking statements.
For more information about Oragenics, visit www.oragenics.com.
Follow Oragenics on Facebook and Twitter.
Copyright Business Wire 2013